<DOC>
	<DOC>NCT01671787</DOC>
	<brief_summary>This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).</brief_summary>
	<brief_title>A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B</brief_title>
	<detailed_description>This is a randomized, open-label, active-controlled study whose primary objective is to evaluate the safety and efficacy of several doses of GS-7340. This study will evaluate the safety, viral kinetics, and antiviral activity of 4 different doses of GS-7340 over 28 days of therapy. In addition, the study will evaluate the antiviral activity of an optimal dose of GS-7340 versus 300mg Tenofovir disoproxil fumarate (TDF) over 28 days of therapy.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Must be between 18 and 65 years of age Must have Screening plasma HBV DNA ≥ 2x10^3 IU/mL Must have chronic HBV infection for at least 6 months Must have estimated creatinine clearance (CLCr) ≥ 70 mL/min Not pregnant or nursing Women must be of nonchildbearing potential OR of childbearing potential with confirmed negative pregnancy tests Consistent and correct use of recommended methods of birth control for men and women Pregnant or lactating subjects Receipt of antiHBV nucleoside/nucleotide therapy. Subjects who have failed prior Interferon treatment, greater than 6 months prior to screening, are permitted to participate in the study screening Known coinfection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV) Presence of autoimmune disorders History of liver disease other than Hepatitis B History of Gilbert's Disease Any sign of decompensated liver disease Known or suspected cirrhosis Evidence of hepatocellular carcinoma Presence or history of cardiovascular disease, cardiomyopathy, and/or cardiac conduction abnormalities Electrolyte abnormalities History of treatment that permanently alters the gastric condition Alcohol or substance abuse History of bleeding diathesis Significant bone disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>GS-7340</keyword>
	<keyword>TDF</keyword>
	<keyword>Tenofovir disoproxil fumarate</keyword>
	<keyword>Gilead</keyword>
	<keyword>Viread</keyword>
</DOC>